Welcome to our dedicated page for Corvus Pharmaceuticals SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Corvus Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Corvus Pharmaceuticals's regulatory disclosures and financial reporting.
Corvus Pharmaceuticals, Inc. appointed David Moore to its Board of Directors effective October 2, 2025. He will serve as a Class III director with a term extending to the 2028 annual meeting of stockholders and will also join the Compensation Committee and the Nominating and Corporate Governance Committee.
Under the company’s non-employee director compensation program, Mr. Moore will receive a $35,000 annual cash retainer for Board service, plus $6,000 annually for serving on the Compensation Committee and $4,000 annually for serving on the Nominating Committee, each earned quarterly and prorated for the current quarter. He will also receive an initial stock option to purchase 30,000 shares of common stock under the 2016 Equity Incentive Award Plan and will be eligible for future equity awards according to the same program. Mr. Moore will enter into the company’s standard indemnification agreement for directors and executive officers.
Corvus Pharmaceuticals, Inc. Schedule 13G/A (Amendment No. 5) was filed by Samlyn Capital, LLC, Samlyn, LP and Robert Pohly reporting zero beneficial ownership of Corvus common stock (CUSIP 221015100) as of the event date 06/30/2025. The filing identifies the reporting persons, their Delaware or U.S. organization, principal office addresses, and confirms 0 shares, 0% ownership with no sole or shared voting or dispositive power. The filing includes Exhibit A (Joint Filing Agreement) and Exhibit B (Control Person Identification) and is signed by Robert Pohly on 08/14/2025.
Form 4 filing for Corvus Pharmaceuticals (CRVS) dated 07/01/2025 details insider transactions by OrbiMed-affiliated entities.
- Warrant exercise: On 06/27/2025, OrbiMed Private Investments V, LP ("OPI V") exercised 1,397,684 common stock warrants at $3.50 per share.
- Cashless settlement: The transaction was executed on a cashless basis. To satisfy the $4.9 million aggregate exercise price, the issuer withheld 1,176,332 warrant shares, issuing the remaining 221,352 shares to OPI V.
- Open-market disposition: Table I also shows a Code "S" disposal of the same 1,176,332 shares at an average price of $4.1586.
- Post-transaction holdings: OrbiMed’s indirect beneficial ownership declined from 8,341,338 to 7,165,006 common shares, but it remains a >10% shareholder and board-represented director.
- Control structure: OPI V is controlled by OrbiMed Capital GP V LLC (general partner) and OrbiMed Advisors LLC (managing member). Each entity disclaims beneficial ownership except to the extent of pecuniary interest.
The filing signals routine warrant housekeeping before the 06/30/2025 expiry rather than a strategic shift. The cashless feature limits share issuance to 221,352 new shares, a modest dilution relative to OrbiMed’s prior stake. Nonetheless, the simultaneous disposition reduces OrbiMed’s ownership by roughly 14%, which investors may view as a slight negative sentiment indicator.
Corvus Pharmaceuticals, Inc. (CRVS) – Form 4 insider activity dated 06/27/2025
Director and 10% owner Peter A. Thompson, acting through OrbiMed Private Investments V, LP (OPI V), exercised 1,397,684 common stock warrants at $3.50 just before their 06/30/2025 expiry. The warrants were settled on a cashless basis: the issuer withheld 1,176,332 shares (coded “S”) to fund the exercise, and issued 221,352 new shares to OPI V (coded “X”). Following the transactions, Thompson/OPI V’s indirect beneficial ownership stands at 7,165,006 shares.
The filing shows a small net increase in insider ownership and a modest share-count expansion for the company. No open-market sales were reported; the disposition reflects internal share withholding rather than a public sale.